BioNTech SE (NASDAQ:BNTX) Shares Acquired by American Century Companies Inc.

Posted by on Sep 2nd, 2023

American Century Companies Inc. lifted its holdings in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 60.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 121,549 shares of the company’s stock after buying an additional 45,856 shares during the period. American Century Companies Inc.’s holdings in BioNTech were worth $15,141,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. raised its position in shares of BioNTech by 178.8% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 74,733 shares of the company’s stock worth $9,309,000 after purchasing an additional 47,924 shares during the period. FORA Capital LLC bought a new stake in BioNTech in the fourth quarter valued at $208,000. Pacer Advisors Inc. boosted its holdings in shares of BioNTech by 162.8% during the fourth quarter. Pacer Advisors Inc. now owns 1,009 shares of the company’s stock valued at $152,000 after acquiring an additional 625 shares during the period. Daiwa Securities Group Inc. grew its position in shares of BioNTech by 14.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,450 shares of the company’s stock worth $368,000 after acquiring an additional 303 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. AG boosted its stake in BioNTech by 1.4% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,366,000 after purchasing an additional 150 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Up 0.7 %

BNTX stock opened at $121.75 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.56 and a quick ratio of 10.32. The firm has a market cap of $29.34 billion, a PE ratio of 6.82 and a beta of 0.18. BioNTech SE has a 12 month low of $95.50 and a 12 month high of $188.99. The firm has a 50 day simple moving average of $109.93 and a 200 day simple moving average of $116.31.

BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.04. The business had revenue of $167.70 million during the quarter, compared to analyst estimates of $628.13 million. BioNTech had a return on equity of 21.46% and a net margin of 47.37%. The company’s revenue was down 94.8% compared to the same quarter last year. During the same period last year, the company posted $7.31 EPS. Equities research analysts forecast that BioNTech SE will post 6.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of recent analyst reports. Morgan Stanley cut their price target on BioNTech from $119.00 to $116.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 8th. HSBC began coverage on BioNTech in a report on Friday, July 14th. They set a “buy” rating and a $124.00 price target on the stock. Redburn Partners raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $165.00 to $170.00 in a report on Wednesday, May 17th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of BioNTech from $135.00 to $120.00 in a research report on Thursday, May 18th. Finally, HC Wainwright restated a “buy” rating and set a $180.00 price target on shares of BioNTech in a research report on Monday, August 28th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $158.69.

Read Our Latest Report on BioNTech

About BioNTech

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Featured Stories

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTX – Free Report).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.